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Abstract 
 
A multitude of factors must be overcome following spinal cord injury (SCI) in order to 
achieve clinical improvement in patients. It is thought that by combining promising 
therapies these diverse factors could be combatted with the aim of producing an 
overall improvement in function. Chondroitin sulphate proteoglycans (CSPGs) present 
in the glial scar that forms following SCI present a significant block to axon 
regeneration. Digestion of CSPGs by chondroitinase ABC (ChABC) leads to axon 
regeneration, neuronal plasticity and functional improvement in preclinical models of 
SCI. However, the enzyme activity decays at body temperature within 24-72 hours, 
limiting the translational potential of ChABC as a therapy. Olfactory ensheathing cells 
(OECs) have shown huge promise as a cell transplant therapy in SCI. Their beneficial 
effects have been demonstrated in multiple small animal SCI models as well as in 
naturally occurring SCI in canine patients. In the present study, we have genetically 
modified canine OECs from the mucosa to constitutively produce enzymatically active 
ChABC. We have developed a lentiviral vector that can deliver a mammalian modified 
version of the ChABC gene to mammalian cells, including OECs. Enzyme production 
was quantified using the Morgan-Elson assay that detects the breakdown products of 
CSPG digestion in cell supernatants. We confirmed our findings by immunolabelling 
cell supernatant samples using Western blotting. OECs normal cell function was 
unaffected by genetic modification as demonstrated by normal microscopic 
morphology and the presence of the low affinity neurotrophin receptor (p75NGF) 
following viral transduction. We have developed the means to allow production of 
active ChABC in combination with a promising cell transplant therapy for SCI repair. 
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Highlights 
 
 Olfactory ensheathing cells from the mucosa can be genetically modified to 
secrete chondroitinase ABC. 
 Lentiviral transduction of olfactory ensheathing cells did not change their 
microscopic morphology or cell marker expression (p75NGF). 
 Chondroitinase ABC production was confirmed using the Morgan-Elson assay 
and Western blot.  
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1. Introduction 
 
Spinal cord injury (SCI) initiates a cascade of biochemical events leading to the 
formation of a glial scar (1, 2). The primary function of the glial scar is to restore the 
blood-spinal cord barrier to prevent an overwhelming inflammatory response following 
SCI (3, 4). However, injured axons are unable to regenerate across the site of injury 
in the central nervous system because of the presence of an array of inhibitory cues 
present within the scar (For a review, see 5, 6), in particular chondroitin sulphate 
proteoglycans (CSPGs) (7-10). Digestion of CSPGs with the bacterial enzyme 
chondroitinase ABC (ChABC), following local delivery to the spinal cord, has led to 
axon regeneration, plastic neuronal rearrangements and functional recovery following 
section or crush injury in laboratory animal SCI models (11-21). Encouragingly, these 
findings have also been found using clinically relevant contusive injury rodent models 
(22, 23) and large animal models such as cats and squirrel monkeys (19, 24, 25). 
Despite these advances, a major limitation for the use of ChABC in humans is the 
rapid decay of enzymatic activity at body temperature, within 24 to 72 hours (26). 
Therefore, serial intraspinal injections or infusion of fresh enzyme is required for 
efficacy. This represents a safety issue for its clinical application that needs to be 
addressed. 
 
A modified variant of the bacterial ChABC gene, capable of producing active enzyme 
from mammalian cells, has recently been developed (27). This sequence has been 
incorporated into both adeno-associated viral vectors and lentiviral vectors as a 
delivery system of the modified ChABC gene into mammalian cells (22, 23, 28, 29). 
Lentiviral vectors transduce host cells efficiently and this results in long-term 
expression of the incorporated transgenes. They also are less immunogenic than other 
viral delivery systems such as adenoviral-based vectors (30, 31). In vivo studies 
testing viral transduction of cells within the spinal cord following intraparenchymal 
injection of a lentiviral vector containing the mammalian form of the ChABC gene 
resulted in widespread CSPGs digestion over several spinal segments and this 
persisted for at least 2 months (22, 23). 
 
Abbreviations 
ChABC, chondroitinase ABC; CSPGs, chondroitin sulphate proteoglycans; MOI, 
multiplicity of infection; NgR ecto, Nogo receptor ectodomain; OECs, olfactory 
ensheathing cells; OMCs, olfactory mucosa cells; p75NGF, anti-nerve growth factor 
receptor; PTPσ, protein tyrosine phosphatase σ; SCI, spinal cord injury; VSVG, 
vesicular stomatitis virus envelope glycoprotein. 
 
Here, we have taken the approach of transducing a population of cells in vitro to 
express the mammalian-modified form of ChABC. Our aim is to develop a new therapy 
that combines the beneficial effects of a cell transplant while allowing sustained 
delivery of ChABC into the site of SCI. It is generally agreed that combining therapies 
for SCI is likely to be more efficient than a single therapy to repair complex lesions 
affecting patients (32-34). ChABC is likely to form an essential component of any 
combination therapy because of its pleotrophic actions that compliment most other 
SCI therapies. It promotes plasticity, is neuroprotective and also has an anti-
inflammatory action by promoting the polarization of macrophages to the anti-
inflammatory M2 type (23).  
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We have chosen to work with olfactory ensheathing cells (OECs), a cell type that has 
been extensively studied for SCI repair. When transplanted into a damaged region of 
the central nervous system OECs can remyelinate, guide and support axons (35, 36). 
They also mediate their effects through the provision of growth factors that encourage 
plasticity, stimulate angiogenesis, interact with the glial scar and are involved in 
immune modulation (For a review, see 37, 38). Their beneficial effect on locomotion 
has been demonstrated in rodent models of SCI (39-43) and in companion dogs (44). 
Further, combining spinal cord injection of OECs and ChABC has a greater effect on 
locomotion and bladder voiding than either therapy alone (45, 46).  
 
In the following sections, we present how canine OECs obtained from the olfactory 
mucosa (i.e. olfactory mucosa cells - OMCs) of companion dogs can be transduced in 
culture with a lentiviral vector to express a functional mammalian-modified form of 
ChABC. 
 
 
2. Materials and Methods 
 
2.1 Lentiviral production 
 
The proteus vulgaris ChABC gene was previously modified to produce a mammalian-
compatible ChABC gene by removing five cryptic N-glycosylation sites, which enabled 
its efficient and functional expression by mammalian cells (27). The mammalian 
ChABC gene was cloned into a lentiviral vector backbone (third-generation transfer 
vector pRRL; (47) to generate pRRL-CMV-ChABC-SFFV-GFP (see LV-ChABC 
construct in Figure 1). Large scale DNA purification of the lentiviral transfer plasmids 
and packaging plasmids were prepared by cesium chloride double ultracentrifugation 
followed by standard DNA precipitation. Lentiviral vectors pseudo typed with the 
vesicular stomatitis virus envelope glycoprotein (VSVG) coat were produced using the 
four plasmid transient transfection protocol as previously described (48). Briefly, 
human embryonic kidney cell (HEK293T) cultures were co-transfected with the 
lentiviral transfer plasmids containing the genes of interest (ChABC and / or GFP), and 
pMDLg/pRRE gag/pol, pMD2-VSVG and pRSV-Rev using lipofectamine mediated 
transfection. The cell supernatant containing viruses was harvested 24 and 48 hours 
post-transfection. Following filtration through a 0.45 μm Nalgene filter unit (Fisher 
Scientific, Loughborough, UK) the supernatant was concentrated 2000-fold by 
ultracentrifugation and the resultant viral pellet was re-suspended in TSSM (20 mM 
tromethamine, 100 mM NaCl, 10 mg/mL sucrose and 10 mg/mL mannitol) buffer. Viral 
vector titres were determined by flow cytometry (FACScalibur flow cytometer, BD 
Biosciences, New Jersey). 
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Figure 1. Schematic drawings of the transfer plasmids containing chondroitinase ABC 
and green fluorescent protein (LV-ChABC) in (a), and only green fluorescent protein 
(LV-GFP) in (b), to be incorporated into lentiviral vectors. GFP is under the control of 
a SFFV promoter in (a) and under the control of a CMV promoter in (b). LV-ChABC 
contains the mammalian-modified ChABC gene under the control of a CMV promoter 
in (a). Both vectors contain the cis-acting WPRE and the cPPT to enhance transgene 
expression and transduction efficiency and both plasmids contain the AmpR to allow 
for selective growth in Escherichia coli bacteria. 
AmpR, ampicillin resistance; ChABC, chondroitinase ABC; CMV, cytomegalovirus 
promoter; cPPT, central polypurine tract; GFP, Green fluorescent protein; LTR, long 
terminal repeat; SFFV, spleen focus forming virus promoter; SV40 Poly(A), simian 
virus 40 polyadenylation signal; WPRE, woodchuck hepatitis post-transcriptional 
regulatory element. 
 
 
 
2.2 Cell cultures  
 
Olfactory mucosa cells were collected from fresh canine cadavers within 10 minutes 
of euthanasia. These animals were companion dogs presented to our clinic and 
euthanized for medical reasons independent of this work; consent was obtained from 
the animals’ owner and ethical permission was granted by our local ethical committee 
(Veterinary Investigation Number: 13/033). Cells were collected via endoscopic nasal 
mucosa biopsy and prepared according to previously published methods (49). Briefly, 
they were maintained in culture medium containing DMEM, 10% FBS, 2 µM forskolin 
and 20 ng/mL neuregulin-1. HEK293T cells were cultured in DMEM, 10% FBS, 2 mM 
L-Glutamine and 1 x MEM. HeLa cells were cultured  in DMEM, 10% FBS and 2 mM 
L-Glutamine and Neu7 cells in DMEM and 10% FBS. All culture media was 
supplemented with 1% penicillin and streptomycin. All cells in culture were maintained 
by replacing half of the media with fresh media every 3-4 days.  
 
2.3 Cell transduction 
 
LV - ChABC 
(a) 
LV - GFP 
(b) 
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For transduction experiments, OMCs, HEK293T cells and HeLa cells were passaged 
into 24 well plates (1.9 cm2 diameter wells) at 40 x 103 cells/cm2. Replicates of at least 
3 wells per experimental condition were performed. Cells were transduced with the 
lentiviral vector containing pRRL-CMV-ChABC-SFFV–GFP (LV-ChABC) at varying 
multiplicities of infection (MOI) from 1 to 20 or pRRL-CMV-GFP (LV-GFP) at MOI 1, to 
act as a negative control for ChABC production. Viral vector was added at 1 day in 
vitro and cell supernatant samples were collected 7 days following transduction. 
Replicate OMC cultures were grown in 4 well plates on glass coverslips for 
immunocytochemistry. For Western blot samples CSPG rich media was added to cell 
cultures 24 hours prior to collection. The CSPG rich media was obtained from Neu7 
cell culture media as previously described by Muir et al (27). 
 
2.4 Immunocytochemistry 
 
Cells were fixed with 4% paraformaldehyde for 10 minutes and immunolabeled using 
mouse anti-nerve growth factor receptor (p75NGF) (MAB5264, Millipore, Germany; 
1:200), rabbit anti-fibronectin (A0245, Dako, Denmark; 1:400) and chicken anti-GFP 
(Abcam; 1:2000). Secondary antibodies were anti-mouse 546 (Abcam, UK; 1:500), 
anti-rabbit 660 (Abcam, UK; 1:400) and anti-chicken 488 (Abcam, UK; 1:500). 
Coverslips were mounted using hard-set mounting medium containing DAPI 
(Vectashield). The transduction efficiency at varying MOI was calculated using ImageJ 
by counting the number of p75NGF positive cells (OECs) that were also GFP positive 
for each MOI. Immunocytochemistry was not performed on HEK293T or HeLa cell 
cultures as they were used primarily to measure ChABC production from differing cell 
lines. 
 
 
 
2.5 Western blots 
 
Proteins were separated by sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) followed by Western blotting. Briefly, samples were 
combined with 5 x non-reducing Laemmli sample buffer (1:4), boiled for 2 minutes, 
separated by SDS-PAGE (5% acrylamide gel) and wet transferred onto a 
nitrocellulose membrane prior to Western blotting. Samples of concentrated cell 
culture supernatants were used to detect intact CSPGs or their digestion products. 
CSPG rich media incubated with commercial ChABC (C3667, Sigma-Aldrich, UK; 20 
mU) for 3 hours at 37°C was used as a positive control for CSPG digestion. LV-GFP 
media was used as a negative control. Primary antibodies were mouse anti-NG2 
(sc33666, Santa Cruz, Texas; 1:1000), mouse anti-C4S (63651, MP Biomedicals, 
California; 1:250) and rabbit anti-chondroitinase ABC polyclonal anti-peptide antibody 
(from Dr. Elizabeth Muir, University of Cambridge). Membranes were blocked in 5% 
semi-skimmed milk for 1 hour at room temperature and then incubated in primary 
antibody, diluted in blocking solution, overnight at 4°C. Membranes were washed with 
tris-buffered saline with tween (TBS-T) prior to incubating in secondary antibody for 1 
hour at room temperature. Secondary antibody was either horseradish peroxidase 
linked anti-mouse IgG (NA931, GE Healthcare, UK; 1:10,000) or anti-rabbit IgG 
(NA934, GE Healthcare, UK; 1:10,000). Membranes were then washed in TBS-T 
before applying Amersham ECL prime Western blotting detection reagent (RPN2232, 
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GE Healthcare, UK). Blots were visualised on Amersham ECL hyperfilm (28906837, 
GE Healthcare, UK). 
 
2.6 In vitro Morgan-Elson enzyme assay 
 
This assay (50) detects the breakdown products of CSPG digestion. N-acetylation of 
the disaccharide products cleaved from CSPGs when exposed to active ChABC 
enzyme results in a colored product. The assay was more recently adapted to allow a 
quantitative measure of active ChABC enzyme concentration using a 
spectrophotometer to quantify the resultant color change (27). The reaction mixture 
consists of 100 µL of 40 mM sodium acetate, 40 mM Tris-Cl (pH=8.0) and 10 mg/mL 
chondroitin-6-sulphate (substrate) mixed with 50 µL of sample (i.e. the cell 
supernatant). N-acetyl-galactosamine was added to one tube to act as a positive 
control. The reaction was incubated at 37°C for 20 minutes then boiled for 1 minute to 
stop the reaction. 100 µL of 0.8 M potassium tetraborate tetrahydrate solution was 
added and the mixture was boiled for 7 minutes before being cooled on ice. 1 mL of 
glacial acetic acid was added and samples were then centrifuged at 10,000 rpm for 33 
minutes. The resultant supernatant was transferred to new 1.5 mL tubes and 0.4 mL 
of Morgan-Elson reagent (10 g paradimethylamino-benzaldehyde in 100 mL of glacial 
acetic acid containing 12.5% hydrochloric acid) was added and incubated at 37°C for 
20 minutes. Absorbance was measured at 550 nm in a disposable cuvette. ChABC 
enzyme units per mL were calculated using a formula (Appendix EqA.1) that takes into 
account absorbance readings compared to blank (water) and the positive control (N-
acetyl-galactosamine). With regard to the final enzyme concentration, one unit will 
liberate 1.0 μmol of 2-acetamido-2-deoxy-3-O-(β-D-gluc-4-ene-pyranosyluronic acid)-
6-O-sulfo-D-galactose from chondroitin-6-sulfate per minute at pH=8.0 at 37°C. 
Morgan-Elson assays for each experiment were run in a single day using the same 
solutions across all samples. All results are expressed as mean (standard deviation). 
 
 
3. Results 
 
3.1 Phenotypic examination of transduced canine olfactory mucosa cultures 
 
In order to test whether lentiviral vector mediated gene transfer or transgene 
expression caused changes in OMC characteristics, cultures of OMCs were 
phenotypically examined under high magnification for cell morphology and the 
expression of cell markers classically used for OEC identification (i.e. p75NGF) and 
OMC culture contaminants (i.e. fibronectin). Based on the terminology proposed by Li 
et al (42) these fibronectin positive cells are known as olfactory nerve fibroblasts. 
There was no change in cell morphology or cell marker expression when comparing 
control cell cultures with virally transduced cultures (Figure 2a, 2b and 2d, 2e 
respectively). Virally transduced cells can be identified by the expression of GFP 
(Figure 2d, 2f). Both cultures showed p75NGF positive cells with a bipolar and elongated 
morphology (Figure 2b, 2e and 2f) as previously described (44, 49, 51). In contrast, 
the fibronectin positive olfactory nerve fibroblasts, often present in olfactory mucosa 
cultures (52) had a flat, rounded appearance (Figure 2c and 2g) and on average 
represented 12% (SD = 3%) of the cells in all cultures. Quantification of the proportion 
of p75NGF positive cells in olfactory mucosa cultures is presented in Figure 3c.  
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Figure 2. The morphology of cells in canine olfactory mucosa cultures and p75NGF 
marker expression was unaffected by lentiviral vector transduction with LV-ChABC. 
Higher magnification images of highlighted regions from (a) and (d) are represented 
below each low magnification image. Panels a, b and c are from control cultures 
whereas panels d, e, f and g are from transduced cultures. Lentivirally transduced 
p75NGF cells (i.e. olfactory ensheathing cells - OECs) display a typical bipolar 
morphology and p75NGF expression (d, e, f) comparable to control olfactory mucosa 
cultures not exposed to virus (a, b). Olfactory nerve fibroblasts, making up a mean of 
12% of olfactory mucosa cultures, display a more rounded morphology and express 
fibronectin but not p75NGF (c, g). Virally transduced cells express the reporter protein 
GFP (d, f) whereas non-transduced cells do not (a, b). DAPI staining represents cell 
nuclei. Scale bar in (a) and (d) is 100 µm and 10 µm in (b, c, e, f and g).  
 
3.2 Lentiviral transduction and purity of canine olfactory mucosa cultures 
 
Two lentiviral vectors were used to transduce HEK293T, HeLa and OMCs in culture 
(Figure 1). The LV-GFP construct was used as a negative control as it does not contain 
the ChABC transgene. The LV-ChABC construct contains the ChABC transgene along 
with the GFP reporter gene. OMCs produced GFP following lentiviral transduction, 
allowing quantification of the transduction efficiency of the viral vector (Figure 3a and 
DAPI/P75 
DAPI/Fibronectin DAPI/Fibronectin 
DAPI/P75/Fibronectin/GFP 
DAPI/P75 
LV-ChABC 
 
Control 
 
DAPI/P75/GFP 
DAPI/P75/Fibronectin 
(a) 
(b) (c) 
(d) 
(e) (f) (g) 
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3b). At MOI 1 the percentage transduction of LV-ChABC was very low. With increasing 
MOI the percentage transduction reached 34% (SD = 2%) at MOI 10. At MOI 1 the 
percentage transduction of LV-GFP was similar to that seen in LV-ChABC at MOI 5. 
The cell counts per microscopic field, used to calculate the cell culture purity, did not 
decrease with increasing MOI and cells continued to expand, suggesting cell survival 
was unaffected by viral transduction.  
  
Olfactory mucosa cultures contained >85% p75NGF positive cells (Figure 3c). This was 
determined based on the proportion of p75NGF positive cells identified from 
immunocytochemistry of OMC cultures divided by the total number of DAPI positive 
cells per field. The remaining cells were likely to be contaminating olfactory nerve 
fibroblasts often present in olfactory mucosa cultures (Figure 2). Increasing MOI of 
lentiviral transduction did not significantly affect cell culture purity (Figure 3c) and the 
number of p75NGF positive cells contributing to this data did not vary with increasing 
MOI.  
  
 
Figure 3. Transduction efficiency using LV-GFP or LV-ChABC and the purity of canine 
olfactory mucosa cultures. (a) Representative immunofluorescent images of canine 
OMC cultures stained with p75NGF and GFP following transduction with LV-GFP (top 
LV-ChABC MOI 1 
DAPI/p75/GFP 
LV-ChABC MOI 5 
 
DAPI/p75/GFP 
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left image) and or with LV-ChABC at multiplicity of infection (MOI) 1, 5 and 10; there 
is an increasing expression of the reporter protein GFP; DAPI staining represents cell 
nuclei in blue - scale bar, 100 µm; (b) Graph representing the percentage transduction 
of canine OMCs expressing p75NGF with LV-GFP and with varying MOI of LV-ChABC. 
Percentage transduction reached 34% with MOI 10; (c) Graph representing the 
percentage of p75NGF positive cells in OMC cultures out of the total number of cells in 
culture; OMC cultures contained >85% p75NGF positive cells and this percentage 
remained relatively constant with varying MOI. 
 
 
 
3.3 Production of active ChABC from genetically modified canine olfactory 
mucosa cultures 
 
Functional ChABC was detectable in cell supernatants of LV-ChABC transduced cell 
cultures (Figure 4). Enzyme concentrations increased with increasing MOI. This 
correlates with the increasing percentage transduction of cells at increasing MOI as 
shown in Figure 3c. Enzyme units were determined using the Morgan-Elson assay 
that detects active enzyme by detecting a breakdown product of CSPG digestion. At 
MOI 10, ChABC concentrations reached 0.09 (SD = 0.01) U/mL in canine OMCs 
(Figure 4a). The ChABC enzyme production for the GFP negative control cells was 
recorded as 0.004 (SD = 0.00) U/mL, not zero, due to a small degree of error in the 
Morgan-Elson assay, and is highly unlikely to be due to the presence of ChABC given 
the make up of the vector construct. Levels of functional ChABC also increased with 
increasing MOI in lentivirally transduced HEK293T cell (Figure 4b) and HeLa cell 
(Figure 4c) supernatants. In HEK293T cell cultures, ChABC concentrations rose to 
0.12 (SD = 0.01) U/mL at MOI 10, higher than the concentration of 0.09 (SD = 0.01) 
U/mL found using canine OMCs. There was a greater than 2 fold difference in ChABC 
concentrations between HEK293T and HeLa cell cultures with concentrations of 0.12 
(SD = 0.01) U/mL in HEK293T cells at MOI 10 (Figure 4b) and 0.05 (SD = 0.01) U/mL 
in HeLa cells at MOI 10 (Figure 4c).  
 12 
 
 
Figure 4. Chondroitinase ABC concentration measured in cell culture supernatant 
from genetically modified OMCs in (a), from HEK239T cells in (b) and from HeLa cells 
in (c). LV-GFP transduced cells were used as negative controls as the vector does not 
contain the ChABC transgene.  
 
 
3.4 ChABC produced by canine olfactory mucosa cultures digest CSPGs 
 
To further demonstrate that functional ChABC was produced by canine OMCs, we 
performed Western blotting to detect CSPGs, their digestion products and ChABC 
(Figure 5). Conditioned media containing CSPGs from Neu7 cells was incubated with 
transduced OMCs for 24 hours. As a positive control (+), media containing CSPGs 
was incubated with commercial ChABC for 3 hours at 37°C (Figure 5a and b, lane 1). 
The negative control (-) was the same media without exposure to ChABC (Figure 5a 
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and b, lane 2). In supernatant from LV-ChABC transduced canine OMCs, a core 
protein band was detected by NG2 immunolabelling (Figure 5a, lane 3), whereas 
conditioned media incubated in the presence of LV-GFP transduced cells 
demonstrated the characteristic smear of the intact CSPG, NG2 (Figure 5a, lane 4). 
Conversely, conditioned media incubated with OMCs incorporating LV-ChABC, 
demonstrated the presence of the C4S CSPG stub region that is only exposed 
following ChABC digestion (Figure 5b, lane 3). As expected, no C4S stubs were 
detected in conditioned media incubated with OMCs incorporating LV-GFP (Figure 5b, 
lane 4). ChABC was detected in supernatant from LV-ChABC transduced OMCs but 
absent from LV-GFP transduced OMCs (Figure 5c). 
  
 
 
 
Figure 5. Enzymatically active mammalian chondroitinase ABC (ChABC) is secreted 
from genetically modified canine OMCs. CSPG rich media was added to cell 
supernatants 24 hours prior to sampling for Western blots, and labelled with antibodies 
to: (a) the CSPG NG2; (b) C4S, the carbohydrate stub revealed by ChABC activity; 
and (c) ChABC. The first two lanes in (a) and (b) are positive and negative controls 
respectively. Commercial ChABC was incubated with CSPG rich media for the positive 
control (+) whereas CSPG rich media alone was used for the negative control (-). 
Olfactory mucosa cultures were transduced with either LV-ChABC or LV-GFP seven 
days prior to sampling. (a) NG2: this appears as a characteristic smear due to the 
glycosaminoglycan (GAG) side-chains in undigested CSPGs (lane 2). This is 
converted to a core protein by digestion with commercial ChABC (lane 1). OMCs 
incorporating LV-ChABC convert the CSPG NG2 from a characteristic smear to core 
protein, demonstrating digestion of the GAG side-chains (lane 3). As expected, there 
is no change in the characteristic smear with media from OMCs transduced with LV-
GFP. (b) C4S: this labels CSPG stubs only revealed by ChABC digestion (lane 1). No 
immunoreactivity is seen with the negative control (lane 2). OMCs incorporating LV-
ChABC digest CSPG revealing the C4S stub (lane 3) whereas LV-GFP cells 
demonstrate no ChABC activity (lane 4). (c) ChABC: non-glycosylated ChABC 
produces a band at around 110 kDa. This was seen in cell supernatant of LV-ChABC 
OMCs (lane 1) but not LV-GFP OMCs (lane 2).  
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 4. Discussion 
 
In this study, we have shown that canine OMCs can be genetically modified to produce 
a functional ChABC enzyme. We chose to use cells of canine origin collected from the 
olfactory mucosa to allow further development of a genetically modified cell transplant 
for testing in the canine model of SCI (44, 53, 54). Dogs suffer a high rate of thoraco-
lumbar SCI caused by mixed contusive-compressive disc herniation, similar to thoracic 
injuries sustained by humans. Using dogs with SCI is advantageous because their 
injuries recapitulate the clinical characteristics of SCI seen in human patients, 
including their heterogeneity, extent and complexity. Therefore, detection of functional 
improvement in the canine model is likely to translate into meaningful clinical benefits 
in people with SCI.  
 
The collection of olfactory mucosa was done using a minimally invasive technique 
using nasal endoscopy, a methodology that can be repeated in human patients and 
represents a low risk procedure for cell collection (55, 56). It allows collection of cells 
from individual patients for autologous transplantation, overcoming the problem of 
possible immune rejection. Ruitenberg et al (57) purified their OEC cultures, using a 
technique that multiple other groups have performed (39, 42, 58, 59). Using our culture 
methods for canine OMCs, adapted from Jeffery et al (54), we achieved p75NGF 
positive OEC purities of >85% (Figure 3c). We chose not to purify these cultures, with 
the aim of eliminating olfactory nerve fibroblasts, as research has shown that a 
combination of OECs and olfactory nerve fibroblasts may be required to see the 
positive effects of these cell transplants (44, 60, 61).  
 
Significant quantities of functional ChABC were detectable in cell supernatants of 
monolayers of lentivirally transduced OMCs without the need to concentrate samples. 
A previous study producing chondroitinase AC (from Pedobacter heparinus) using an 
adenoviral vector required cell supernatants to be concentrated for detection of 
enzyme (62). However, the absolute concentrations of ChABC produced are difficult 
to compare to previous in vitro data (27, 28, 62, 63) due to variations in experimental 
protocols and enzyme detection methods.  
 
Multiple strategies have been developed to remove the axon inhibitory properties of 
CSPGs at the site of SCI (for a review, see 64). Degradation of CSPG side-chains 
using ChABC has been established as one approach for over a decade (11). As 
previously discussed, repeated delivery of enzyme, to overcome the problem of rapid 
loss of activity at body temperature, has hindered the translational potential of this 
therapy. One group has taken the approach of thermo-stabilizing ChABC and 
achieved sustained delivery of the enzyme for up to 6 weeks using a hydrogel-
microtube scaffold (65). Other groups have pursued gene therapy as a means to 
improve sustained enzyme delivery (22, 23, 28, 29, 62, 63). An alternative approach 
to disabling the inhibitory CSPGs is to target the CSPG receptor present on neurons: 
protein tyrosine phosphatase σ (PTPσ) (66). Competitive inhibition of the receptor for 
PTPσ using a peptide mimetic of PTPσ has been shown to improve urinary function in 
rats (67).  Effective knockout of PTPσ using lentiviral delivery of small interfering RNAs 
also led to motor and sensory recovery along with neurite outgrowth (68). However, it 
has also been shown that the products of CSPG enzymatic digestion encourage 
neurite outgrowth and have an immunomodulatory role in inflammatory central 
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nervous system lesions (69, 70). Therefore, targeting a specific CSPG receptor such 
as PTPσ, may not produce all the beneficial effects of ChABC.    
 
The combination of OECs and ChABC (plus a Schwann cell graft) has already been 
tested in a complete spinal cord transection model where the addition of ChABC 
improved both bladder and motor function (45, 46). The feasibility of genetically 
modifying OECs from the olfactory bulb for SCI was previously demonstrated by 
Ruitenberg et al (57). OECs expressing GFP using a lentiviral vector were 
transplanted into the injured rat spinal cord and transgene expression persisted in 
transplanted OECs for at least 4 months. If the ChABC transgene could be expressed 
for a similar length of time this is likely to be an adequate timeframe to promote axonal 
regeneration and plasticity in chronic SCI. Indeed, the same mammalian-modified 
ChABC transgene presented here has previously been shown to produce active 
ChABC for 2 months following injection into the injured spinal cord (23) and 3 months 
following lentiviral transduction of a Schwann cell transplant (28). More recently 
Reginensi, Carulla (71) genetically modified OECs from the bulb to produce the Nogo 
receptor ectodomain (NgR ecto). This NgR ecto binds to myelin-associated inhibitors 
preventing their binding to the NgR complex present on axons and removing the 
inhibitory properties of myelin breakdown products following SCI. NgR ecto also 
increased OEC migration in vitro and in vivo, a mechanism thought to be key to their 
function (72). Increased migration was also found over CSPG substrates with the 
addition of ChABC. In future studies, we will examine the migratory properties of our 
ChABC-expressing OECs.  
 
The plasmid construct presented here (Figure 1a) is capable of producing both GFP 
and ChABC via different internal promoters, SFFV and CMV respectively. It was noted 
that the intensity of GFP as a result of the LV-GFP construct (Figure 1b), where GFP 
is under the influence of a CMV promoter, was significantly higher than the GFP 
produced by the LV-ChABC construct (Figure 4). This is likely due to the efficacy of 
the different promoters. This may have artificially elevated the transduction percentage 
of the LV-GFP construct at MOI 1 as cells were more easily identified during 
microscopy and cell counting. This may also indicate that the transduction percentage 
of the LV-ChABC construct could be higher than presented if a more powerful 
promoter was used for the expression of GFP. The co-expression of GFP using these 
constructs will aid tracking of cell transplants in experimental models, providing more 
accurate information on transplant survival, location and migration.  
 Previous studies have used a MOI of up to 1000 in adult rat OECs to achieve 
transduction percentages close to 100% whereas parallel experiments in HEK293T 
cells only required a MOI of just 25 (57). We refrained from using such high MOI in our 
OEC cultures as even at our relatively low transduction rates sufficient ChABC was 
secreted. This was comparable to concentrations that have produced significant 
functional improvements in vivo in rat SCI models (11, 16). Despite the robust levels 
of ChABC seen in vitro, it is possible that a proportion of OMCs will not survive 
following SCI transplantation (73). Therefore, with our current transduction efficiency 
of 34%, there may not be enough surviving ChABC-producing cells at the site of injury 
to achieve the desired in vivo efficacy. This will be addressed in future experiments by 
documenting the degree of CSPG digestion in vivo following transplantation of this 
genetically modified cell type. However, if necessary we can increase the transduction 
percentage of the OMCs by using fluorescence-activated cell sorting to select OMCs 
expressing GFP (74, 75), and therefore ChABC, leading to a cell transplant with closer 
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to 100% transduction. It should be noted that from a clinical standpoint, OMC 
transplants are more likely to be given in the ‘chronic’ phase of SCI, at which point cell 
survival is greater than with acute transplantation (73). Clinical transplantation 
protocols will also include injection of cells cranial and caudal to the lesion, allowing 
cells to migrate into the lesion (76), which could also improve efficacy. In preliminary 
work we have seen active ChABC produced for the 2-week period of cell culture 
following transduction and the levels of enzyme produced tend to increase over time 
(see Supplementary Figure 1). In future experiments we will assess ChABC production 
over longer time frames in vitro and by transplanted OMCs in vivo. We anticipate that 
OMCs surviving transplantation will stop dividing to ensheath and re-myelinate axons.  
   
 5. Conclusion 
 
We have provided here a method to genetically modify OECs to secrete active 
ChABC. In addition, co-expression of GFP will aid future in vivo work using this 
engineered cell type. Transplantation of OECs holds great promises for spinal cord 
repair because their efficacy to restore locomotion has been shown in several models 
including the canine natural model of SCI, although they do not seem to help recovery 
of brain controlled functions. We propose that combining OECs with ChABC, as we 
have done here, might further enhance the potential of OEC transplants to restore 
these complex neurological functions. 
 
 
 
 
Supplementary Figure 1. Chondroitinase ABC concentration in cell culture 
supernatants from a separate line of canine genetically modified OMCs kept in culture 
for 14 days. The initial cell numbers used for these experiments were lower than those 
used in Figure 4 in order to avoid cells reaching confluence within 7 days, hence the 
lower overall ChABC concentrations.   
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Appendix 
 
Enzyme 
Unit = A585 x 0.1 x 1 x 1 
(U/mL)  2.38  G  10  E 
 
EqA.1 - Mathematical formula for determining ChABC enzyme concentration following 
Morgan-Elson assay. Abbreviations: A585, sample absorbance minus blank 
absorbance; G, standard absorbance minus blank absorbance; E, volume of enzyme 
solution. 
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